Share this article on:

Manufacturers News

doi: 10.1097/01.HJ.0000516784.76658.15
Manufacturers News

Manufacturers News covers the latest products, programs, and news from hearing health care companies. News releases and photographs are welcome. Please submit information to

Back to Top | Article Outline


Sound Pharmaceuticals ( will be using its award of up to $1.6 million from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to conduct initial testing of a new drug, SPI-1005, that will reduce the incidence and severity of sensorineural hearing loss and tinnitus in several disease states, including ototoxicity, noise, and Ménière's disease. The STOP Ototoxicity clinical trial will begin initial testing of SPI-1005 in cystic fibrosis (CF) patients who are taking tobramycin to treat acute pulmonary exacerbations or lung infections. Damage to the inner ear is a side effect of tobramycin. The clinical trial, which will enroll 100 subjects at different U.S. sites, will examine the incidence and severity of hearing loss, tinnitus, dizziness, or vertigo due to IV tobramycin.

Patrick Flume, MD, professor of medicine and pediatrics at Medical University of South Carolina, will be leading the research. “This is the first comprehensive U.S. study of ototoxicity in the CF population, and we are pleased to be leading it,” Flume said. Currently, there are no FDA-approved drugs for the prevention or treatment of any type of sensorineural hearing loss, tinnitus, ototoxicity, and Ménière's disease, according to Sound Pharmaceuticals.

Back to Top | Article Outline


Howard Leight by Honeywell ( has released an upgrade to its earplug fit-test software VeriPRO 4.0 to improve its speed, reliability, and usability. With better navigation and new graphics, VeriPRO 4.0 is compatible with Windows 10/7 platforms, and is available in 12 languages. It is offered as a free online upgrade for existing VeriPRO users. First launched in 2008, VeriPRO is a three-part system that includes software, headphones, and audio processor, and checks the effectiveness of an employee's earplug fit in each ear over a range of frequencies.

Back to Top | Article Outline


Phonak ( is releasing a new marketing campaign by Terri & Sandy for its completely invisible Phonak Lyric hearing aid to encourage people who need treatment for their hearing loss to seek help earlier. The ads will feature couples in intimate moments with bold headlines like “My midlife crisis is obvious. My hearing aid is not,” and “Tonight, I'm wearing nothing but my hearing aid.” The campaign uses tongue-in-cheek humor to show how hearing aids are not a barrier to connecting with others but a solution to help people live life to the fullest. Susan Whichard, vice president of business development and industry relations, said this campaign allowed the company to break down barriers for whom Lyric can help. “Lyric3 features improved reliability and two additional sizes. Now, more wearers can benefit by choosing the world's only 24/7, invisible device with trusted Phonak hearing performance,” Whichard said.

Besides being 100 percent invisible, Phonak Lyric allows for extended wear, minimizing the hassle of having to take it out, put it on, and turn it off regularly. The device also lasts for a long time, and does not require frequent changes of battery. The placement of Lyric close to the ear drum utilizes the ear's natural anatomy to facilitate a more natural sound.

Back to Top | Article Outline


Interacoustics Academy ( has announced a new series of live webinars for spring 2017 on the latest diagnostic insights and clinical trends in audiologic and vestibular technologies and their applications. There will be a live webinar on P300 on May 12, one on cVEMP on May 24, and another on advanced tests in audiometry on June 7. The Academy's experts, including Eric Schneider, PhD, from EyeSeeTech in Munich, Germany, will present the one-hour webinars. These sessions are also recorded for anyone who would like to view them later. More information is available on the event's web page (

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.